
iGlarLixi provides earlier, superior glycaemic control than Gla-100. In Asian patients with suboptimally controlled T2D, iGlarLixi reduced HbA1c more than Gla-100 (LixiLan-O-AP: −1.6% vs. −1.1%; LixiLan-L-CN: −1.3% vs. −0.5%). PPG reductions were greater, while FPG reductions and hypoglycaemia rates were similar. Median time to HbA1c and PPG targets was significantly shorter. These findings highlight iGlarLixi’s advantage for early glycaemic control.
Like
Save
Share